Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164155 | 0.87 | BRAF (0.65) | BRAFRAF1YES1MAPK14KDM4E | |
| SCHEMBL4168270 | 0.85 | MAPK14 (0.62) | BRAFRAF1YES1MAPK14KDM4E | |
| SCHEMBL4168731 | 0.82 | MAPK14 (0.68) | BRAFRAF1YES1MAPK14KDM4E | |
| SCHEMBL4166616 | 0.82 | BRAF (0.64) | BRAFRAF1YES1MAPK14KDM4E | |
| SCHEMBL4170220 | 0.82 | MAPK14 (0.62) | BRAFRAF1YES1MAPK14KDM4E | |
| SCHEMBL27701740 | 0.82 | BRAF (0.59) | BRAFRAF1YES1MAPK14KDM4E | |
| SCHEMBL27702012 | 0.81 | BRAF (0.65) | BRAFRAF1YES1MAPK14 | |
| SCHEMBL27682651 | 0.81 | MAPK14 (0.62) | BRAFRAF1YES1MAPK14KDM4E | |
| SCHEMBL20133847 | 0.81 | BRAF (0.69) | BRAFRAF1YES1MAPK14KDM4E | |
| SCHEMBL14691162 | 0.80 | KDM4E (0.63) | BRAFRAF1YES1MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | BRAF, NRAS, RAF1 | BRAF 1/4885RAF1 3/4885YES1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.